“In summary, this study reported improved survival when allo-HTC was performed in CR1 versus after later lines of therapy.”
BUFFALO, NY- October 11, 2024 – A new editorial was published in Oncotarget's Volume 15 on October 1, 2024, entitled, “ Transplant or no transplant for TP53 mutated AML .”
As highlighted in this editorial, TP53 mutations (mut) occur in 10–15% of acute myeloid leukemia (AML) cases, commonly associated with therapy-related AML (t-AML) and complex cytogenetics (CG). TP53-mut AML is inherently resistant to conventional chemotherapies and continues to show a poor prognosis, even with venetoclax-based therapies. Allogeneic hematopoietic stem cell transplant (allo-HCT) remains a potential curative option, though only 10–15% of patients receive it. In a recent study, allo-HCT was the only variable significantly improving survival, despite only 16% of patients successfully bridging to it.
In their editorial, researchers Talha Badar, Moazzam Shahzad, Ehab Atallah, Mark R. Litzow, and Mohamed A. Kharfan-Dabaja from the Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program at Mayo Clinic (Jacksonville, Florida) evaluated the outcomes of TP53-mutated AML patients based on data from the Consortium of Myeloid Malignancies and Neoplastic Diseases (COMMAND). The study found a “dismal” survival rate of 8.5 months, with no significant difference among treatment types, and allo-HCT was the only variable associated with improved survival.
The authors also report on the “better long-term outcomes” when allo-HCT was performed during Complete Remission 1 (CR1) in previous observations. They acknowledge the limitations of their retrospective analysis, including selection bias, data heterogeneity from participating institutions, and the lack of complete molecular data prior to allo-HCT that might have influenced the results. Nevertheless, the findings are encouraging and suggest that allo-HCT improves long-term outcomes in this poor prognostic disease, where effective therapies remain limited.
“ In summary, this study reported improved survival when allo-HTC was performed in CR1 versus after later lines of therapy. ”
Continue reading: DOI: https://doi.org/10.18632/oncotarget.28652
Correspondence to : Talha Badar - badar.talha@mayo.edu
Keywords: cancer, AML, TP53 mutation, allogeneic stem cell transplant
Click here to sign up for free Altmetric alerts about this article.
About Oncotarget :
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived by PubMed/Medline , PubMed Central , Scopus , EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget , visit Oncotarget.com and connect with us on social media:
X
Facebook
YouTube
Instagram
LinkedIn
Pinterest
Spotify , and available wherever you listen to podcasts
Click here to subscribe to Oncotarget publication updates.
For media inquiries , please contact media@impactjournals.com .
Oncotarget Journal Office
6666 East Quaker St., Suite 1
Orchard Park, NY 14127
Phone: 1-800-922-0957 (option 2)
Oncotarget
Commentary/editorial
Not applicable
Transplant or no transplant for TP53 mutated AML
1-Oct-2024
Authors have no conflicts of interest to declare.